Table 1. Completed clinical trials of tofacitinib in pcJIA populations.

pcJIA: Polyarticular course juvenile idiopathic arthritis; JIA: Juvenile idiopathic arthritis; NSAIDs: Non-steroidal anti-inflammatory drugs.

Author, Year	Study Population	Results and Findings	Conclusions
Ruperto N et al., 2017 [22]	Patients aged 2 to 18 years and currently diagnosed with JIA. If treated, the patients must be on stable doses of NSAIDs, corticosteroids, or methotrexate.	Clearance and volume of distribution of tofacitinib was shown to decrease with age and have no adverse side effects that resulted in discontinuation of the medication.	In conclusion, the study confirms dosing regimens and acceptable taste for further studies to investigate efficacy.
Ruperto N et. al., 2021 [24]	Patients aged 2 to 18 years old and currently diagnosed with JIA and patients being treated should be on stable methotrexate.	The study found that flare-up rates are significantly lower in the tofacitinib group (29%) compared to placebo (59%). Adverse events reported in 77% of the tofacitinib group, while only 74% of placebo group.	This study concluded that tofacitinib is an effective treatment for JIA in pediatric populations.